COMMUNIQUÉS West-GlobeNewswire

PacBio to Participate in the Jefferies Global Healthcare Conference
21/05/2026
MENLO PARK, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat [...]
Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21/05/2026
SAN JOSE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first of-its-kind technology to improve clinical outcomes in dialysis with less cost and [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
21/05/2026
CONSHOHOCKEN, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis [...]
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21/05/2026
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting [...]
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
21/05/2026
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage therapeutics company focused on developing transformative therapies targeting functional cures for immunological disorders, [...]
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
21/05/2026
REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development
21/05/2026
IRVINE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it expects to fully [...]
NervGen Announces Proposed Public Offering of Securities
21/05/2026
The Base Shelf Prospectus is, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or [...]
Inventiva to Present at 2026 Jefferies Global Healthcare Conference
21/05/2026
Daix (France), New York (United States), May 21, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies [...]
Inventiva présentera lors de la 2026 Jefferies Global Healthcare Conference
21/05/2026
Daix (France), New York City (New York, Etats-Unis), le 21 mai 2026 – Inventiva (Euronext Paris et Nasdaq : IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une [...]
ODDIFACT Receives European Commission Orphan Drug Designation for Infliximab in Kawasaki Disease
21/05/2026
European designation follows U.S. FDA Orphan Drug Designation previously granted for the same indication Landmark KIDCARE trial demonstrated superiority of infliximab over standard retreatment in resistant Kawasaki [...]
ODDIFACT obtient la désignation médicament orphelin de la Commission Européenne pour l’infliximab dans la maladie de Kawasaki
21/05/2026
La désignation de la Commission Européenne fait suite à la désignation médicament orphelin de la FDA américaine, précédemment accordée pour la même indication L’essai clinique KIDCARE a démontré la supériorité de l’ [...]
BulkGLP Announces Dual-Tier Quality Verification Protocol for Global Supply of Analytical Reference Materials
21/05/2026
Exclusive manufacturing partnership integrates point-of-origin batch testing in Malaysia with strict domestic HPLC and LC-MS verification to ensure uncompromising purity for laboratory reagents. BulkGLP Logo DALLAS, May [...]
NMDP Gala in New York City Raises Record-Breaking $660,000 Enabling More Patients to Receive Life-Saving Cell Therapy
21/05/2026
Sanofi Honored with Corporate Leadership Award; Wanda and Robert Zimmer Serve as Honorary Chairs; Sherry Graves Hope Fund for Patient Financial Support Established MINNEAPOLIS, May 21, 2026 (GLOBE NEWSWIRE) -- NMDP℠ [...]
The Joint Corp. Announces Milind Pant Elected as Director
21/05/2026
- Global Executive with Extensive Digital and International Franchise-Led Growth Experience - SCOTTSDALE, Ariz., May 21, 2026 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest franchisor of [...]
IQity and Sightpath Medical Partner to Deliver Advanced Ophthalmic Technology to Surgeons Nationwide
21/05/2026
RENO, Nev., May 21, 2026 (GLOBE NEWSWIRE) -- IQity, the developer of a revolutionary integrated diagnostic and surgical platform for modern ophthalmology, today announced a strategic partnership with Sightpath Medical, [...]
Seven Arrows Recovery Expands Public Education Efforts Around Forward Facing, Nervous System Centered Addiction Treatment
21/05/2026
The Arizona residential treatment center introduces broader awareness of its trauma informed and salutogenic recovery model through Forward Facing Accelerated Recovery™ Elfrida, ARIZONA, May 21, 2026 (GLOBE NEWSWIRE [...]
Paul Cobbo to head leading Brisbane NDIS provider Orange Plan Management
21/05/2026
Brisbane, QUEENSLAND, May 21, 2026 (GLOBE NEWSWIRE) -- Paul Cobbo has been appointed General Manager of nationally recognised NDIS plan manager Orange Plan Management. He brings a decade of experience with him gained [...]
The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults
21/05/2026
The olanzapine long-acting injectable ( TEV-’749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation 1 administered every four weeks. If approved, TEV-‘749 could help fill a significant [...]

Pages